Coya Therapeutics (COYA) Other Non Operating Income (2022 - 2026)
Coya Therapeutics (COYA) reported Other Non Operating Income of $433227.0 for Q1 2026, up 17.04% on a YoY basis from $370165.0 in Q1 2025, and up 33.12% sequentially from $325435.0 in Q4 2025.
Coya Therapeutics (COYA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 5 years of Other Non Operating Income data on file, last reported at $433227.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 17.04% year-over-year to $433227.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 12.12% YoY), and the FY2025 full-year result was $1.3 million, down 19.19% from the prior year.
- Other Non Operating Income climbed to $433227.0 in Q1 2026, from $325435.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $444232.0 in Q4 2024 to a low of -$3017.0 in Q1 2022.
- A 5-year average of $242182.9 and a median of $317066.0 in 2025 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income surged 5523.73% in 2023 and slipped 26.74% in 2025, its largest moves.
- Tracing COYA's Other Non Operating Income over 5 years: stood at $16330.0 in 2022, then jumped by 969.64% to $174672.0 in 2023, then surged by 154.32% to $444232.0 in 2024, then decreased by 26.74% to $325435.0 in 2025, then soared by 33.12% to $433227.0 in 2026.
- Business Quant data shows COYA's Other Non Operating Income at $433227.0 in Q1 2026, $325435.0 in Q4 2025, and $317066.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - |
| 10 | Coya Therapeutics | 91.71 Mn | 40.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 433,227.00 |
| Dec 31, 2025 | 325,435.00 |
| Sep 30, 2025 | 317,066.00 |
| Jun 30, 2025 | 319,541.00 |
| Mar 31, 2025 | 370,165.00 |
| Dec 31, 2024 | 444,232.00 |
| Sep 30, 2024 | 428,871.00 |
| Jun 30, 2024 | 344,445.00 |
| Mar 31, 2024 | 431,089.00 |
| Dec 31, 2023 | 174,672.00 |
| Sep 30, 2023 | 142,089.00 |
| Jun 30, 2023 | 158,970.00 |
| Mar 31, 2023 | 163,634.00 |
| Dec 31, 2022 | 16,330.00 |
| Sep 30, 2022 | 39,420.00 |
| Jun 30, 2022 | 10,940.00 |
| Mar 31, 2022 | -3,017.00 |